| News

Basilea receives grant for novel antibiotic

20.05.2021

The CARB-X initiative is granting a sum of 2.7 million US dollars to the Basel-based pharmaceuticals company Basilea. This will support development of an antibiotic from a novel active substance class. With its program, Basilea is fighting infections from resistant bacteria.

The public-private consortium CARB-X led by the University of Boston grants funding for the development of medicines to diagnose, prevent and treat drug-resistant bacteria. Now CARB-X has granted Basilea 2.7 million US dollars of funding according to a press release from the Basel-based pharmaceutical company. Basilea is already running a support program to develop an antibiotic from a novel active substance class to treat infections by drug-resistant, Gram-negative bacteria.

Laurenz Kellenberger, Chief Scientific Officer at Basilea, is quoted in the press release saying: “The medical problem of antimicrobial resistance keeps increasing.” The company develops drugs to treat cancer and infections. From summer 2022, it will be settled in the Switzerland Innovation Park Basel Area Main Campus in Allschwil in the canton of Basel-Landschaft. The new innovation campus is currently being built and upon completion will become the main campus of the Switzerland Innovation Park Basel Area run by Basel Area Business & Innovation. With the program being newly funded by CARB-X, Basilea is also pursuing a new approach.

As such, Basilea plans to develop an inhibitor for the DXR enzyme. This enzyme is needed by some Gram-negative bacteria that the World Health Organisation has classed as dangerous “priority pathogens”. Kellenberger adds: “We are delighted to be partnering with CARB-X for the development of truly innovative antibiotics directed against this unexploited bacterial target. Basilea remains committed to leverage its proven ability in the discovery, development and commercialization of novel anti-infectives to deliver new treatment options to patients facing bacterial drug-resistance worldwide.”

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Ontotext opens new office in the Basel Area
Basel Area Business & Innovation, Innovation, Invest, Switzerland Innovation Park

Ontotext opens new office in the Basel Area

Ontotext, a company based in New York City and the Bulgarian capital of Sofia, has opened a new location at...

Read More
Owkin heads to Basel
Basel Area Business & Innovation, Innovation, Invest

Owkin heads to Basel

The Franco-US startup Owkin is establishing a branch office in Basel. The company develops solutions for the life sciences industry...

Read More
Danish AI company settling in the Basel Area
Basel Area Business & Innovation, Innovation, Invest, Switzerland Innovation Park

Danish AI company settling in the Basel Area

Abzu has settled on the Novartis Campus of the Switzerland Innovation Park Basel Area. From there, the Danish deep tech...

Read More
«I always wanted to create something from scratch»
Basel Area Business & Innovation, Innovation, Invest, Switzerland Innovation Park

«I always wanted to create something from scratch»

Already when he was young, he was driven to create and invent. Today at the age of 33, Gwenael Hannema...

Read More
The i4Challenge announces the winners of 2021
Basel Area Business & Innovation, Innovation

The i4Challenge announces the winners of 2021

The i4Challenge shines a light on companies and innovators who help to facilitate the industrial transformation. We present the winners...

Read More
Basel Area becomes the Swiss hotspot for Chinese pharma companies
Basel Area Business & Innovation, Innovation, Invest

Basel Area becomes the Swiss hotspot for Chinese pharma companies

More and more Chinese pharmaceutical companies are choosing the Basel Area as location for their subsidiary in Switzerland. Among them...

Read More
1 2 3 18

Do you have a question? We'd like to hear from you.